Survival and Treatment of Ovarian Lymphoma, Whether Primary or Secondary, with a Focus on DLBCL, Diffuse large b-cell Lymphoma type: A Literature Review Based on the yun et al Study
International Journal of Development Research
Survival and Treatment of Ovarian Lymphoma, Whether Primary or Secondary, with a Focus on DLBCL, Diffuse large b-cell Lymphoma type: A Literature Review Based on the yun et al Study
Received 20th February, 2024; Received in revised form 11th March, 2024; Accepted 09th April, 2024; Published online 30th May, 2024
Copyright©2024, Donatello. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Object: To describe the treatment and survival of OL (ovarian lymphoma) both primary and secondary. Method: Review of the literature (the study by Yun et al). Discussion: The review points out how the R-CHOP protocol appears to be superior to CHOP alone in terms of response and relapse rate in the case of secondary lymphoma ovarian involvement in DLBCL type. The HyperCVAD regimen is effective in other histotyps.The estimated five-year survival rates for primary and secondary ovarian involvement by DLBCL-type lymphoma are 70.0% and 59.3%, respectively. Conclusion: The study deducts that patients with primary ovarian NHL appear to have similar outcome with patients with other NHL. They, thus recommend a treatment with curative intent by a combination of chemotherapy regimens appropriate for their specific histology.On the other hand other studies are necessary.
